Equities

Milestone Pharmaceuticals Inc

MIST:NSQ

Milestone Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.55
  • Today's Change0.000 / 0.00%
  • Shares traded232.87k
  • 1 Year change-49.18%
  • Beta1.7117
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

  • Revenue in USD (TTM)0.00
  • Net income in USD-48.41m
  • Incorporated2003
  • Employees47.00
  • Location
    Milestone Pharmaceuticals Inc420-1111 boul. Dr.-Frederik-PhilipsMONTREAL H4M 2X6CanadaCAN
  • Phone+1 (514) 336-0444
  • Fax+1 (514) 336-0444
  • Websitehttps://www.milestonepharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PMV Pharmaceuticals Inc0.00-48.88m77.79m63.00--0.363-----0.9662-0.96620.004.160.00----0.00-20.38-21.16-21.39-21.91------------0.00------5.94--16.31--
Sellas Life Sciences Group Inc0.00-34.44m78.49m16.00--24.19-----0.934-0.9340.000.05040.00----0.00-204.48-111.48-838.03-184.29-------1,289.42----0.00---100.00--9.59------
Omega Therapeutics Inc6.31m-78.90m78.87m93.00--3.00--12.49-1.43-1.430.11450.47620.0318--6.6767,892.48-39.72---46.68-------1,249.54------0.3917--49.25--5.13------
Renovaro Inc0.00-88.12m79.76m11.00--0.473-----1.08-1.080.001.140.00----0.00-60.56-27.81-68.21-28.44-----------24.380.0405------65.02---0.1538--
Bioatla Inc0.00-104.56m80.24m65.00--2.56-----2.18-2.180.000.64910.00----0.00-84.23-48.72-106.06-57.35-------6,651.71----0.00-------15.95---37.01--
Vistagen Therapeutics Inc970.40k-33.19m81.03m41.00--0.7732--83.50-1.53-1.530.03863.870.0151----24,882.05-51.63-62.84-56.12-68.03-----3,420.44-5,768.52----0.00--568.10--50.44---18.91--
Cidara Therapeutics Inc31.58m-116.17m81.78m69.00--0.4055--2.59-25.49-25.306.9528.660.2617--8.06457,623.20-96.27-65.23-136.45-154.3791.14---367.91-100.61----0.0053---0.8425--31.72--23.33--
Milestone Pharmaceuticals Inc0.00-48.41m82.57m47.00--2.58-----1.01-1.010.000.60030.00----0.00-51.98-48.44-55.36-51.56-------1,267.25----0.6171---80.00---2.22--86.23--
Adlai Nortye Ltd (ADR)5.00m-54.07m82.66m127.00--1.55--16.53-6.21-6.210.24651.45------39,370.08-------------1,081.30------0.4255-------78.38------
Aclaris Therapeutics Inc32.02m-58.68m83.47m91.00--0.6237--2.61-0.8267-0.82670.45091.880.1614--84.70351,824.20-29.58-47.29-32.76-53.8742.6344.00-183.28-549.18----0.00--5.0338.41-1.81---0.703--
Benitec Biopharma Inc7.00k-21.69m84.32m18.00--1.98--12,045.71-9.87-9.870.00314.220.0006--0.1284388.89-186.85-83.43-260.89-98.771,542.8696.86-309,885.70-468.04---307.030.00--2.74-53.84-7.44---56.51--
Genelux Corp8.00k-26.54m84.61m23.00--2.22--10,576.49-0.9704-0.97040.00031.110.0002----347.83-69.34---84.43-------331,725.00------0.00---98.46---443.44------
Regencell Bioscience Holdings Ltd0.00-4.71m84.71m12.00--8.34-----0.362-0.3620.000.7810.00----0.00-37.91---37.91--------------0.00------21.15------
Beyondspring Inc1.88m-15.57m86.04m35.00------45.86-0.3987-0.39870.0481-0.7490.0698----52,111.11-59.75-75.50-102.15-96.48-----856.29-4,977.12--------29.61--36.82---13.54--
Data as of Sep 19 2024. Currency figures normalised to Milestone Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

44.12%Per cent of shares held by top holders
HolderShares% Held
BlackRock Financial Management, Inc.as of 30 Jun 20244.71m8.84%
RTW Investments LPas of 30 Jun 20243.26m6.11%
Millennium Management LLCas of 30 Jun 20242.75m5.16%
Alta Fundamental Advisers LLCas of 14 Jul 20242.66m4.99%
Lion Point Capital LPas of 30 Jun 20242.34m4.39%
Citadel Advisors LLCas of 30 Jun 20242.12m3.98%
Nantahala Capital Management LLCas of 30 Jun 20241.75m3.29%
Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 20241.35m2.54%
Bleichroeder LPas of 30 Jun 20241.33m2.49%
Stonepine Capital Management LLCas of 30 Jun 20241.24m2.33%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.